

REMARKS

Claim 2 has been amended. Claims 1, 3, 6-8, 10-12, 14-15, 20-22, 24-27, 31, and 36-37 have been canceled. Claims 2, 4, 5, 9, 10, 16-19, 23, 28-30 and 32-35 are pending in the application. Claims 16-19, 23, 28-30 and 32-35 are withdrawn from consideration.

Claim 2 has been amended to even further clarify that at least one of said 351 oligonucleotides may be replaced, wherein the one of said 351 oligonucleotides may be replaced with either (i) an oligonucleotide fragment of the one of said 351 oligonucleotides being replaced, which fragment is at least 20 nucleotides in length, (ii) an oligonucleotide having a sequence entirely complementary to the one of said 351 oligonucleotides being replaced, or to a fragment thereof which is at least 20 nucleotides in length, or (iii) an oligonucleotide having at least 80% identity to the one of said 351 oligonucleotides being replaced or to a fragment thereof which is at least 20 nucleotides in length. Support for the amendments to claim 2 may be found at least at page 6, lines 18-26, page 7, lines 5-11, page 10, line 7, page 9, lines 10-25, and page 11, lines 7-12 of the specification.

No new matter is added.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

/Tu A. Phan/

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Tu A. Phan, Ph.D.
Registration No. 59,392

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: August 11, 2009